Alzheimer’s disease market expected to reach $14.7bn across the 8MM by 2033
The Alzheimer’s disease market is expected to grow at a high compound annual growth rate (CAGR) of 20.0% from $2.4 …
Post
-
-
BMS’s Zenbexus meets PFS endpoint in pivotal multiple myeloma trial
Bristol Myers Squibb’s (BMS’s) Phase III trial of Zenbexus (iberdomide) has more than doubled progression-free survival (PFS) in patients with …
-
MimiVax announces disappointing pivotal Phase IIb trial data for cancer vaccine
The pivotal SURVIVE Phase IIb trial for SurVaxM, a glioblastoma (GBM) peptide-mimic immunotherapeutic cancer vaccine developed by MimiVax, announced interesting …
-
Argenx cans Phase III Vyvgart Sjögren’s study on predicted efficacy fail
Argenx has terminated a late-stage trial evaluating its marketed therapy, Vyvgart Hytrulo (efgartigimod alfa, hyaluronidase-qvfc) in Sjögren's syndrome – dashing …
-
Lantern Pharma secures Taiwan clearances for Phase II NSCLC study
Lantern Pharma has secured regulatory and Institutional Review Board (IRB) clearances in Taiwan to initiate Part 2 of its Phase …
-
Podcast: Customising clinical trials without increasing patient burden
As highly specialised advances in clinical research have grown, so has the burden on clinicians, caregivers, and trial participants to …
-
Dignify Therapeutics secures FDA clearance for Phase I DTI-117 trial
Dignify Therapeutics has secured investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to advance DTI-117 …
-
ArriVent’s stock plummets on Phase III NSCLC trial failure
ArriVent BioPharma’s stock has dropped 46% after a Phase III trial of its non-small cell lung cancer (NSCLC) candidate failed …
-
Cerevance’s novel Parkinson’s drug nets a Phase III win
Boston-based biotech Cerevance’s first-in-class Parkinson’s therapy, solengepras, has demonstrated its potential to improve both motor and non-motor symptoms in a …
-
Taiho’s CMO Dr Keer on positive REZILIENT3 data for zipalertinib combo
Taiho Oncology chief medical officer (CMO) Dr Harold Keer recently discussed with Srivani Venna the outcomes from the Phase III REZILIENT3 …
-
FDA agrees ENABLE-2 Phase III trial design for Enliven’s relcobatinib
Enliven Therapeutics has reached an agreement with the US Food and Drug Administration (FDA) regarding the final protocol for the …
-
How advances in drug discovery are changing the path from research to clinical trials
Vini Jain, content and research team partner at Compound Vitality, explains how certain advancements in the preclinical stage are improving …
-
OCT SoCal 2026: Sound governance and collaboration lead the way as regulation percolates
Astutely managed clinical operations (clin-ops) are a foundational part of consistent and successful clinical trial execution. For the multiple stakeholders involved …
-
Viking Therapeutics begins study of oral VK2735 for obesity
Viking Therapeutics has commenced the second part of a clinical trial evaluating oral maintenance dosing schedules of its dual glucagon-like …
-
ViiV Healthcare’s Cabenuva beats daily oral ART in Phase IIIb trial
ViiV Healthcare’s long-acting HIV treatment Cabenuva showed superior rates of viral suppression compared with oral antiretroviral therapy (ART) in adults …
